Avaliação do perfil clínico e epidemiológico de pacientes em uso do dupilumabe no controle da dermatite atópica moderada a grave

Abstract

Introduction: Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly affects patients’ quality of life. Dupilumab is the first biologic therapy approved in Brazil for the treatment of moderate to severe AD. Objectives: To characterize the sociodemographic and clinical profile, as well as disease severity, of the participants. To evaluate the progression of clinical scores at three time points in order to assess therapeutic response. To investigate the correlation between score variations, particularly between baseline and week 16. Methods: Adult patients with na indication for dupilumab use and access to the medication were included, all under regular follow-up at the service during the study period. After the first application, they were evaluated at weeks 0, 4 and 16. At each visit, disease activity and severity, pruritus intensity and impact on quality of life were measured using the instruments EASI (Eczema Area and Severity Index), IGA (Investigator’s Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numerical Rating Scale for itch), and DLQI (Dermatology Life Quality Index). Results: A statistically significant variation (p < 0.0001) was observed over time across all assessment scores, including SCORAD, EASI, NRS, IGA, and DLQI. The EASI demonstrated a 71% reduction from baseline to week 16. Significant correlations were found among the assessment scales. Adverse events were limited to facial erythema and conjunctivitis. Conclusions: Dupilumab resulted in significant clinical improvement. The consistent use of tools such as IGA, EASI, SCORAD, NRS, and DLQI is strongly recommended for monitoring patient outcomes.